Literature DB >> 15567570

Potentiation of human alpha4beta2 neuronal nicotinic receptors by a Flustra foliacea metabolite.

Francisco Sala1, José Mulet, Krishna P Reddy, José Antonio Bernal, Philip Wikman, Luis Miguel Valor, Lars Peters, Gabriele M König, Manuel Criado, Salvador Sala.   

Abstract

The effects of various Flustra foliacea metabolites on different types of human neuronal nicotinic acetylcholine receptors (nAChRs) expressed in Xenopus oocytes were investigated. Whereas most of the compounds tested had a small blocking effect, one of them, deformylflustrabromine, selectively increased the current obtained in alpha4beta2 receptors when co-applied with acetylcholine (ACh). The current increase was reversible and concentration-dependent. This potentiating effect was still present at saturating concentrations of acetylcholine, and no changes in single-channel conductance or reversal potential were observed, thus suggesting a modification in the gating of alpha4beta2 receptors. Dwell time analysis of single channel records indicates that the mechanism of action of deformylflustrabromine could be both an increase of the opening rate constant and a decrease of the closing rate constant on alpha4beta2 receptors. Thus, deformylflustrabromine may constitute an excellent starting point for the future development of related agents able to potentiate human neuronal nicotinic receptor function.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15567570     DOI: 10.1016/j.neulet.2004.10.002

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  27 in total

1.  Allosteric modulation of alpha4beta2 nicotinic acetylcholine receptors by HEPES.

Authors:  Maegan M Weltzin; Yanzhou Huang; Marvin K Schulte
Journal:  Eur J Pharmacol       Date:  2012-06-23       Impact factor: 4.432

2.  Desformylflustrabromine (dFBr) and [3H]dFBr-Labeled Binding Sites in a Nicotinic Acetylcholine Receptor.

Authors:  Ayman K Hamouda; Ze-Jun Wang; Deirdre S Stewart; Atul D Jain; Richard A Glennon; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2015-04-13       Impact factor: 4.436

3.  Unraveling amino acid residues critical for allosteric potentiation of (α4)3(β2)2-type nicotinic acetylcholine receptor responses.

Authors:  Ze-Jun Wang; Farah Deba; Tasnim S Mohamed; David C Chiara; Kara Ramos; Ayman K Hamouda
Journal:  J Biol Chem       Date:  2017-04-26       Impact factor: 5.157

4.  Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors.

Authors:  M Grupe; A A Jensen; P K Ahring; J K Christensen; M Grunnet
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 5.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations.

Authors:  Dustin K Williams; Jingyi Wang; Roger L Papke
Journal:  Biochem Pharmacol       Date:  2011-05-14       Impact factor: 5.858

6.  Effects of nicotine in combination with drugs described as positive allosteric nicotinic acetylcholine receptor modulators in vitro: discriminative stimulus and hypothermic effects in mice.

Authors:  Megan J Moerke; Fernando B de Moura; Wouter Koek; Lance R McMahon
Journal:  Eur J Pharmacol       Date:  2016-05-27       Impact factor: 4.432

Review 7.  Nicotinic acetylcholine receptors in neuropathic and inflammatory pain.

Authors:  Arik J Hone; J Michael McIntosh
Journal:  FEBS Lett       Date:  2017-10-27       Impact factor: 4.124

Review 8.  Recent progress in neuroactive marine natural products.

Authors:  Ryuichi Sakai; Geoffrey T Swanson
Journal:  Nat Prod Rep       Date:  2014-01-17       Impact factor: 13.423

9.  Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration.

Authors:  Xiu Liu
Journal:  Psychopharmacology (Berl)       Date:  2013-05-28       Impact factor: 4.530

10.  Photolabeling a Nicotinic Acetylcholine Receptor (nAChR) with an (α4)3(β2)2 nAChR-Selective Positive Allosteric Modulator.

Authors:  Ayman K Hamouda; Farah Deba; Ze-Jun Wang; Jonathan B Cohen
Journal:  Mol Pharmacol       Date:  2016-03-14       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.